The API Tolterodine tartrate (Y20230000094) held by Jiudian HongYang, a wholly-owned subsidiary of Jiudian Pharmaceutical, has been registered in CDE with the status of “A” in June, 2024.

Tolterodine tartrate is a novel competitive M-receptor antagonist with good tissue selectivity and is clinically used for the treatment of overactive bladder (OBA), such as urinary frequency, urgency, and urge incontinence. Clinical studies have demonstrated that tolterodine tartrate  significantly reduces the frequency of voiding and the number of episodes of incontinence, and increases the average volume of each voiding, with the advantages of rapid onset of action, long duration, and few side effects.

The prevalence of OAB increases with age. According to 2011 data, the overall prevalence of OAB in China is 6%, and the prevalence of OAB in people aged 41 and above is 11.3%, which is still increasing. Yaorongyun data show that in 2022, the domestic sales of tolterod in tartrate preparations was nearly 100 million, and with the acceleration of China's aging process, the future market development space will continue to expand. 

OAB has became a common dysfunctional disease in the lives of middle-aged and elderly people, with considerable market demand, scale and development prospects. The successful conversion of Tolterodine Tartrate to “A” has laid a solid foundation for the marketing of the product, and will further improve our competitiveness and consolidate our market position.